Dose-response modeling of NLRP3 inflammasome-mediated diseases: asbestos, lung cancer, and malignant mesothelioma as examples

References

• Abderrazak A, Syrovets T, Couchie D, El Hadri K, Friguet B, Simmet T, Rouis M. 2015. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 4:296–307.
   PubMed Web of Science ®Google Scholar
• Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL. 2018. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 142(6):753–760.
   PubMed Web of Science ®Google Scholar
• Baas P, Burgers JA. 2014. Is one single exposure to asbestos life-threatening? Ned Tijdschr Geneeskd. 158:A7653.
   PubMedGoogle Scholar
• Baroja-Mazo A, Martín-Sánchez F, Gomez AI, Martínez CM, Amores-Iniesta J, Compan V, Barberà-Cremades M, Yagüe J, Ruiz-Ortiz E, Antón J, et al. 2014. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 15(8):738–748.
   PubMed Web of Science ®Google Scholar
• Berman DW, Crump KS. 2008. Update of potency factors for asbestos-related lung cancer and mesothelioma. Crit Rev Toxicol. 38(sup1):1–47.
   PubMed Web of Science ®Google Scholar
• Bernstein DM. 2014. The health risk of chrysotile asbestos. Curr Opin Pulm Med. 20(4):366–370.
   PubMed Web of Science ®Google Scholar
• Bittoni MA, Carbone DP, Harris RE. 2017. Ibuprofen and fatal lung cancer: a brief report of the prospective results from the Third National Health and Nutrition Examination Survey (NHANES III). Mol Clin Oncol. 6(6):917–920.
   PubMed Web of Science ®Google Scholar
• Bogen KT. 2019. Inflammation as a cancer co-initiator: new mechanistic model predicts low/negligible risk at non-inflammatory carcinogen doses. Dose Response. 17(2):155932581984783.
   Web of Science ®Google Scholar
• Borm PJA, Schins RPF, Albrecht C. 2004. Inhaled particles and lung cancer, part B: paradigms and risk assessment. Int J Cancer. 110(1):3–14.
   PubMed Web of Science ®Google Scholar
• Borm P, Cassee FR, Oberdörster G. 2015. Lung particle overload: old school -new insights? Part Fibre Toxicol. 12(1):10.
   PubMedGoogle Scholar
• Browne K. 1991. Asbestos related malignancy and the Cairns hypothesis. Br J Ind Med. 48(2):73–76.
   PubMedGoogle Scholar
• Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI, Yang H. 2012. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 227(1):44–58.
   PubMed Web of Science ®Google Scholar
• Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS. 2011. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets. 15(9):1127–1137.
   PubMed Web of Science ®Google Scholar
• Churg A. 1982. Fiber counting and analysis in the diagnosis of asbestos-related disease. Hum Pathol. 13(4):381–392.
   PubMed Web of Science ®Google Scholar
• Comar M, Zanotta N, Zanconati F, Cortale M, Bonotti A, Cristaudo A, Bovenzi M. 2016. Chemokines involved in the early inflammatory response and in pro-tumoral activity in asbestos-exposed workers from an Italian coastal area with territorial clusters of pleural malignant mesothelioma. Lung Cancer. 94:61–67.
   PubMed Web of Science ®Google Scholar
• Cox LAT. Jr. 2018. Biological mechanisms of non-linear dose-response for respirable mineral fibers. Toxicol Appl Pharmacol. 361:137–144.
   PubMed Web of Science ®Google Scholar
• Cox L. 2019. Risk analysis implications of dose-response thresholds for NLRP3 inflammasome-mediated diseases: respirable crystalline silica and lung cancer as an example. Dose-Response. 17(2):155932581983690.
   Web of Science ®Google Scholar
• Cox LA. Jr. 2006. Universality of J-shaped and U-shaped dose-response relations as emergent properties of stochastic transition systems. Dose Response. 3(3):353–368.
   PubMedGoogle Scholar
• DeStefano A, Martin CF, Wallace DI. 2017. A dynamical model of the transport of asbestos fibres in the human body. J Biol Dyn. 11(1):365–377.
   PubMed Web of Science ®Google Scholar
• Donaldson K, Poland CA, Murphy FA, MacFarlane M, Chernova T, Schinwald A. 2013. Pulmonary toxicity of carbon nanotubes and asbestos – similarities and differences. Adv Drug Deliv Rev. 65(15):2078–2086.
   PubMed Web of Science ®Google Scholar
• Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 320(5876):674–677.
   PubMed Web of Science ®Google Scholar
• Elliott EI, Sutterwala FS. 2015. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev. 265(1):35–52.
   PubMed Web of Science ®Google Scholar
• Frost G. 2013. The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005). Br J Cancer. 109(7):1965–1973.
   PubMed Web of Science ®Google Scholar
• Galani V, Varouktsi A, Papadatos SS, Mitselou A, Sainis I, Constantopoulos S, Dalavanga Y. 2019. The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment. Cancer Chemother Pharmacol. 84(2):241.
   PubMed Web of Science ®Google Scholar
• Gamble JF, Gibbs GW. 2008. An evaluation of the risks of lung cancer and mesothelioma from exposure to amphibole cleavage fragments. Regul Toxicol Pharmacol. 52(1 Suppl):S154–S186.
   Google Scholar
• Gilham C, Rake C, Burdett G, Nicholson AG, Davison L, Franchini A, Carpenter J, Hodgson J, Darnton A, Peto J. 2016. Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med. 73(5):290–299.
   PubMed Web of Science ®Google Scholar
• Gilroy D, Lawrence T. 2008. The resolution of acute inflammation: a ‘tipping point’ in the development of chronic inflammatory diseases. In: Rossi AG, Sawatzky DA (eds). The resolution of inflammation. Progress in inflammation research. Basel: Birkhäuser.
   Google Scholar
• Gomes M, Teixeira AL, Coelho A, Araújo A, Medeiros R. 2014. The role of inflammation in lung cancer. Adv Exp Med Biol. 816:1–23.
   PubMed Web of Science ®Google Scholar
• Grabiec AM, Hussell T. 2016. The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. Semin Immunopathol. 38(4):409–423.
   PubMed Web of Science ®Google Scholar
• Hatna E, Benenson I. 2015. Combining segregation and integration: Schelling model dynamics for heterogeneous population. J Artif Soc Soc Simul. 18(4):1–15.
   Web of Science ®Google Scholar
• Hauenstein AV, Zhang L, Wu H. 2015. The hierarchical structural architecture of inflammasomes, supramolecular inflammatory machines. Curr Opin Struct Biol. 31:75–83.
   PubMed Web of Science ®Google Scholar
• He Q, Fu Y, Tian D, Yan W. 2018. The contrasting roles of inflammasomes in cancer. Am J Cancer Res. 8(4):566–583.
   PubMed Web of Science ®Google Scholar
• Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC, Salter RD. 2013. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol. 191(10):5230–5238.
   PubMed Web of Science ®Google Scholar
• Hillegass JM, Miller JM, MacPherson MB, Westbom CM, Sayan M, Thompson JK, Macura SL, Perkins TN, Beuschel SL, Alexeeva V, et al. 2013. Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol. 10(1):39.
   PubMedGoogle Scholar
• Huang L, Duan S, Shao H, Zhang A, Chen S, Zhang P, Wang N, Wang W, Wu Y, Wang J, et al. 2019. NLRP3 deletion inhibits inflammation-driven mouse lung tumorigenesis induced by benzo(a)pyrene and lipopolysaccharide. Respir Res. :20:20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352353/pdf/12931_2019_Article_983.pdf
   Web of Science ®Google Scholar
• Hutton HL, Ooi JD, Holdsworth SR, Kitching AR. 2016. The NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology (Carlton). 21(9):736–744.
   PubMed Web of Science ®Google Scholar
• Ilgren EB. 2004. The biology of cleavage fragments: a brief synthesis and analysis of current knowledge. Indoor and Built Environment. 13(5):343–356.
   Google Scholar
• Jo EK, Kim JK, Shin DM, Sasakawa C. 2016. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 13(2):148–159.
   PubMed Web of Science ®Google Scholar
• Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. 2012. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem. 287(43):36617–36622.
   PubMed Web of Science ®Google Scholar
• Kadariya Y, Menges CW, Talarchek J, Cai KQ, Klein-Szanto AJ, Pietrofesa RA, Christofidou-Solomidou M, Cheung M, Mossman BT, Shukla A, et al. 2016. Inflammation-related IL1β/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma. Cancer Prev Res (Phila). 9(5):406–414.
   PubMed Web of Science ®Google Scholar
• Kane AB, Hurt RH, Gao H. 2018. The asbestos-carbon nanotube analogy: an update. Toxicol Appl Pharmacol. 361:68–80.
   PubMed Web of Science ®Google Scholar
• Karasawa T, Takahashi M. 2017. Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb. 24(5):443–451.
   PubMed Web of Science ®Google Scholar
• Karki R, Man SM, Kanneganti TD. 2017. Inflammasomes and cancer. Cancer Immunol Res. 5(2):94–99.
   PubMed Web of Science ®Google Scholar
• Kaul H, Ventikos Y. 2015. Investigating biocomplexity through the agent-based paradigm. Brief Bioinform. 16(1):137–152.
   PubMed Web of Science ®Google Scholar
• Kukkonen MK, Hämäläinen S, Kaleva S, Vehmas T, Huuskonen MS, Oksa P, Vainio H, Piirilä P, Hirvonen A. 2011. Genetic susceptibility to asbestos-related fibrotic pleuropulmonary changes. Eur Respir J. 38(3):672–678.
   PubMed Web of Science ®Google Scholar
• Kukkonen MK, Vehmas T, Piirilä P, Hirvonen A. 2014. Genes involved in innate immunity associated with asbestos-related fibrotic changes. Occup Environ Med. 71(1):48–54.
   PubMed Web of Science ®Google Scholar
• Kumagai-Takei N, Yamamoto S, Lee S, Maeda M, Masuzzaki H, Sada N, Yu M, Yoshitome K, Nishimura Y, Otsuki T. 2018. Inflammatory alteration of human T cells exposed continuously to asbestos. Int J Mol Sci. 19(2):504.
   Web of Science ®Google Scholar
• Kuriakose T, Kanneganti TD. 2017. Regulation and functions of NLRP3 inflammasome during influenza virus infection. Mol Immunol. 86:56–64.
   PubMed Web of Science ®Google Scholar
• Lacourt A, Lévêque E, Guichard E, Gilg Soit Ilg A, Sylvestre MP, Leffondré K. 2017. Dose-time-response association between occupational asbestos exposure and pleural mesothelioma. Occup Environ Med. 74(9):691–697.
   PubMed Web of Science ®Google Scholar
• Latz E, Xiao TS, Stutz A. 2013. Activation and regulation of the inflammasomes. Nat Rev Immunol. 13(6):397–411.
   PubMed Web of Science ®Google Scholar
• Lee DK, Jeon S, Han Y, Kim SH, Lee S, Yu IJ, Song KS, Kang A, Yun WS, Kang SM, et al. 2018. Threshold rigidity values for the asbestos-like pathogenicity of high-aspect-ratio carbon nanotubes in a mouse pleural inflammation model. ACS Nano. 12(11):10867–10879.
   PubMed Web of Science ®Google Scholar
• Li M, Gunter ME, Fukagawa NK. 2012. Differential activation of the inflammasome in THP-1 cells exposed to chrysotile asbestos and Libby “six-mix” amphiboles and subsequent activation of BEAS-2B cells. Cytokine. 60(3):718–730.
   PubMed Web of Science ®Google Scholar
• Liu G, Cheresh P, Kamp DW. 2013. Molecular basis of asbestos-induced lung disease. Annu Rev Pathol Mech Dis. 8(1):161–187.
   PubMed Web of Science ®Google Scholar
• MacPherson M, Westbom C, Kogan H, Shukla A. 2017. Actin polymerization plays a significant role in asbestos-induced inflammasome activation in mesothelial cells in vitro. Histochem Cell Biol. 147(5):595–604.
   PubMed Web of Science ®Google Scholar
• Markowitz S. 2015. Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues. Semin Respir Crit Care Med. 36(3):334–346.
   PubMed Web of Science ®Google Scholar
• McCarthy WJ, Meza R, Jeon J, Moolgavkar SH. 2012. Chapter 6: lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal. 32(suppl 1):S69–S84.
   PubMedGoogle Scholar
• Miller JM, Thompson JK, MacPherson MB, Beuschel SL, Westbom CM, Sayan M, Shukla A. 2014. Curcumin: a double hit on malignant mesothelioma. Cancer Prev Res (Phila). 7(3):330–340.
   PubMed Web of Science ®Google Scholar
• Motwani R, Raghavan P. 1995. Randomized algorithms. Cambridge, UK: Cambridge University Press.
   Google Scholar
• Moolgavkar SH, Anderson EL, Chang ET, Lau EC, Turnham P, Hoel DG. 2014. A review and critique of U.S. EPA's risk assessments for asbestos. Crit Rev Toxicol. 44(6):499–522.
   PubMed Web of Science ®Google Scholar
• Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. 2018. Role of the NLRP3 inflammasome in cancer. Mol Cancer. 17(1):158.
   PubMed Web of Science ®Google Scholar
• Offermans NS, Vermeulen R, Burdorf A, Goldbohm RA, Kauppinen T, Kromhout H, van den Brandt PA. 2014. Occupational asbestos exposure and risk of pleural mesothelioma, lung cancer, and laryngeal cancer in the prospective Netherlands cohort study. Occup Environ Med. 56(1):6–19.
   Web of Science ®Google Scholar
• Oh JY, Ko JH, Lee HJ, Yu JM, Choi H, Kim MK, Wee WR, Prockop DJ. 2014. Mesenchymal stem/stromal cells inhibit the NLRP3 inflammasome by decreasing mitochondrial reactive oxygen species. Stem Cells. 32(6):1553–1563.
   PubMed Web of Science ®Google Scholar
• Page SE. 2018. The model thinker. New York, NY: Basic Books.
   Google Scholar
• Palomäki J, Välimäki E, Sund J, Vippola M, Clausen PA, Jensen KA, Savolainen K, Matikainen S, Alenius H. 2011. Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. ACS Nano. 5(9):6861–6870.
   PubMed Web of Science ®Google Scholar
• Paris C, Martin A, Letourneux M, Wild P. 2008. Modelling prevalence and incidence of fibrosis and pleural plaques in asbestos-exposed populations for screening and follow-up: a cross-sectional study. Environ Health. 7(1):30.
   PubMedGoogle Scholar
• Robb CT, Regan KH, Dorward DA, Rossi AG. 2016. Key mechanisms governing resolution of lung inflammation. Semin Immunopathol. 38(4):425–448.
   PubMed Web of Science ®Google Scholar
• Rödelsperger K, Mándi A, Tossavainen A, Brückel B, Barbisan P, Woitowitz HJ. 2001. Inorganic fibres in the lung tissue of Hungarian and German lung cancer patients. Int Arch Occup Environ Health. 74(2):133–138.
   PubMed Web of Science ®Google Scholar
• Ruff K, Mirabelli D, Magnani C. 2016. Scientific journal publishes second eratum regarding false information by scientists funded by asbestos interests. Epidemiol Prev. 40(2):138–139.
   Google Scholar
• Sayan M, Mossman BT. 2016. The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases. Part Fibre Toxicol. 13(1):51.
   PubMedGoogle Scholar
• Schinwald A, Murphy FA, Prina-Mello A, Poland CA, Byrne F, Movia D, Glass JR, Dickerson JC, Schultz DA, Jeffree CE, et al. 2012. The threshold length for fiber-induced acute pleural inflammation: shedding light on the early events in asbestos-induced mesothelioma. Toxicol Sci. 128(2):461–470.
   PubMed Web of Science ®Google Scholar
• Shao BZ, Wang SL, Pan P, Yao J, Wu K, Li ZS, Bai Y, Linghu EQ. 2019. Targeting NLRP3 inflammasome in inflammatory bowel disease: putting out the fire of inflammation. Inflammation. 42(4):1147.
   PubMed Web of Science ®Google Scholar
• Shukla A, Vacek P, Mossman BT. 2004. Dose-response relationships in expression of biomarkers of cell proliferation in in vitro assays and inhalation experiments. Nonlinearity Biol Toxicol Med. 2(2):117–128.
   PubMedGoogle Scholar
• Song N, Li T. 2018. Regulation of NLRP3 inflammasome by phosphorylation. Front Immunol. 9:2305.
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP. 2019. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 19(8):477.
   PubMed Web of Science ®Google Scholar
• Tan E, Warren N. 2011. Mesothelioma mortality in Great Britain: the revised risk and two-stage clonal expansion models. Prepared by the Health and Safety Laboratory for the Health and Safety Executive. Harpur Hill Buxton Derbyshire SK17 9JN. www.hse.gov.uk/research/rrpdf/rr876.pdf
   Google Scholar
• Tezcan G, Martynova EV, Gilazieva ZE, McIntyre A, Rizvanov AA, Khaiboullina SF. 2019. MicroRNA post-transcriptional regulation of the NLRP3 inflammasome in immunopathologies. Front Pharmacol. 10:451.
   PubMed Web of Science ®Google Scholar
• Thompson JK, MacPherson MB, Beuschel SL, Shukla A. 2017. Asbestos-induced mesothelial to fibroblastic transition is modulated by the inflammasome. Am J Pathol. 187(3):665–678.
   PubMed Web of Science ®Google Scholar
• Travis WD, Colby JV, Koss MN, Rosado-de-Christenson ML, Muller NL, King TE. 2002. Non-neoplastic disorders of the lower respiratory tract. In: Roasi J, editor. Atlas of nontumor pathology. Washington DC: American Registry of Pathologists, Armed Forces Institute Pathologists; pp. 814–846.
   Google Scholar
• Tuomi T, Segerberg-Konttinen M, Tammilehto L, Tossavainen A, Vanhala E. 1989. Mineral fiber concentration in lung tissue of mesothelioma patients in Finland. Am J Ind Med. 16(3):247–254.
   PubMed Web of Science ®Google Scholar
• Vlachogianni T, Fiotakis K, Loridas S, Perdicaris S, Valavanidis A. 2013. Potential toxicity and safety evaluation of nanomaterials for the respiratory system and lung cancer. Lung Cancer (Auckl). 4:71–82.
   PubMedGoogle Scholar
• Warheit DB, Kreiling R, Levy LS. 2016. Relevance of the rat lung tumor response to particle overload for human risk assessment – Update and interpretation of new data since ILSI 2000. Toxicology. 374:42–59.
   PubMed Web of Science ®Google Scholar
• Woitowitz HJ, Baur X. 2018. Misleading “new insights into the chrysotile debate”. Pneumologie. 72(7):507–513.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang H, Kouadir M, Song H, Shi F. 2019. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 10(2):128.
   PubMed Web of Science ®Google Scholar
• Zeka A, Gore R, Kriebel D. 2011. The two-stage clonal expansion model in occupational cancer epidemiology: results from three cohort studies. Occup Environ Med. 68(8):618–624.
   PubMed Web of Science ®Google Scholar
• Zhiyu W, Wang N, Wang Q, Peng C, Zhang J, Liu P, Ou A, Zhong S, Cordero MD, Lin Y. 2016. The inflammasome: an emerging therapeutic oncotarget for cancer prevention. Oncotarget. 7(31):50766–50780.
   PubMedGoogle Scholar
• Zhou K, Shi L, Wang Y, Chen S, Zhang J. 2016. Recent advances of the NLRP3 inflammasome in central nervous system disorders. J Immunol Res. 2016:1.
   Google Scholar